This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Intramuscular Ziprasidone, 2 mg Versus 10 mg, in the Short-Term Management of Agitated Psychotic Patients

Michael D. Lesem, John M. Zajecka, Rachel H. Swift, Karen R. Reeves, and Edmund P. Harrigan

Published: January 1, 2001

Article Abstract
Background: There is a clear need for effective, well-tolerated intramuscular (i.m.) agents for the acute control of agitated psychotic patients. Currently used agents, including conventional antipsychotics and/or benzodiazepines, may be associated with distressing side effects such as extrapyramidal side effects and excessive sedation.

Objective: The objective of this study was toevaluate the efficacy and tolerability of the rapid-acting i.m.formulation of the novel antipsychotic ziprasidone in thetreatment of inpatients with psychosis and acute agitation(DSM-IV diagnoses).

Method: In a 24-hour, double-blind, fixed-doseclinical trial, patients were randomly assigned to receive up to4 injections (every 2 hours p.r.n.) of 2 mg (N = 54) or 10 mg (N= 63) of ziprasidone i.m. The Behavioral Activity Rating Scalemeasured behavioral symptoms at baseline and the response totreatment up to 4 hours after the first i.m. injection.

Results: Ziprasidone i.m., 10 mg, rapidlyreduced symptoms of acute agitation and was significantly moreeffective (p < .01) than the 2-mg dose up to 4 hours after thefirst injection. Patients were calmed but not excessivelysedated, and over half were classed as responders 2 hours afterthe 10-mg dose. No acute dystonia or behavioral disinhibition wasreported. One patient who received the 10-mg dose experienced theextrapyramidal side effect akathisia.

Conclusion: Ziprasidone i.m., 10 mg, is rapidlyeffective and well tolerated in the short-term management of theagitated psychotic patient. Comparison with a study of identicaldesign comparing 2-mg with 20-mg doses in patients with similarlevels of psychopathology suggests that efficacy with 10 mg or 20mg of ziprasidone i.m. is significant and dose related.

Volume: 62

Quick Links: Neurologic and Neurocognitive , Neurology

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF